Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Larimar Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with serious or life-threatening diseases.

Reata Pharmaceuticals

A biopharmaceutical company dedicated to the discovery and development of transformative medicines for patients with genetically defined diseases.

Agios Pharmaceuticals

Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an initial focus on Friedreich’s ataxia.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 12, 2024 5:56 PM	2e5b9865
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 12, 2024 5:56 PM	1e07a94c
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	55dd9338
crunchbase profile	general
li profile	general	Feb 12, 2024 5:56 PM	6e994594
translate crunchbase fundingrounds	general
peers	general	Feb 12, 2024 5:56 PM	436c4d1e
news basic	general	Feb 12, 2024 5:56 PM	ada52619
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:LARIMARTX

Larimar Therapeutics

Last Close

6.13

22/11 21:00

Market Cap

584.11M

Beta: -

Volume Today

402.09K

Avg: -